Tromsø, Norway, 22 April 2021 - ArcticZymes Technologies (OSE: AZT) reported
sales of NOK 40.4 million (18.5) and an EBITDA of NOK 25.8 million (9.0) for the
first quarter of 2021.

Highlights from Q1 2021

  · ArcticZymes Technologies (AZT) had Q1 sales of NOK 40.4 million growing by
119% (Q1 2020: NOK 18.5 million)
  · Coronavirus-related sales are estimated at NOK 16.5 million in Q1 2021 (NOK
3.8 million in Q1 2020)
  · Gross profit improved to NOK 39.9 million with 99% margin (Q1 2020: NOK 18.5
Million)

  · AZT delivered a positive EBITDA of NOK 25.8 million (Q1 2020: NOK 9.0
million)

  · Cash-flow for Q1 was positive NOK 23.2 million (Q1 2020: NOK 4.4 million)
giving a cash balance of NOK 163.3 million (Q1 2020: NOK 35.7 million)
  · Successfully upscaled the SAN HQ production process

CEO Jethro Holter comments:

"We are delighted with the performance of our first quarter as a pure enzymes
company. The ArcticZymes team has delivered the best ever quarterly performance
achieving sales revenues of 40 million NOK and an EBITDA of 26 million NOK. All
market segments have experienced quarterly growth including re-establishment of
molecular research sales to pre-pandemic levels.

Furthermore, the SAN HQ enzyme production process was successfully upscaled 100
-fold. The innovation pipeline and the infrastructure expansion project of R&D
and operations are progressing. Such activities are key to leveraging the
greater potential ArcticZymes Technologies can accomplish through organic
growth."

-Ends-

First Quarter 2021 Presentation and Webcast

A presentation by ArcticZymes Technologies' CEO, Jethro Holter and CFO, Børge
Sørvoll will take place today, 22[nd] April 2021, at 08:30 am CET as a live
video/phone -conference.
Call in details: +47 21 40 24 87 with conference id: 246 245 401#. Participants
who want to participate in the Teams webcast are asked to send an email to
ir@arcticzymes.com for a separate invitation.

The results, report and presentation for the first quarter 2021 will be
available on www.newsweb.no (https://protect
-eu.mimecast.com/s/ax_EC4xJkS8gx1SMlEBY?domain=newsweb.no) and on the Company's
homepage www.arcticzymes.com from 07:00 am on 22[th] April 2021.



For more information, please contact:

ArcticZymes Technologies ASA
CEO, Jethro Holter            Tel: +47 46 85 91 46
CFO, Børge Sørvoll            Tel: +47 95 29 01 87
                                ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.